Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study

• Published in: Brain (London, England : 1878) England : 1878), 2022-03, Vol.145 (1), p.340-348
• Main Authors: Holland, Negin, Malpetti, Maura, Rittman, Timothy, Mak, Elijah E, Passamonti, Luca, Kaalund, Sanne S, Hezemans, Frank H, Jones, P Simon, Savulich, George, Hong, Young T, Fryer, Tim D, Aigbirhio, Franklin I, O'Brien, John T, Rowe, James B
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - pathology; Brain - pathology; Carbolines; Carbon Radioisotopes - metabolism; Cross-Sectional Studies; Humans; Original; Pathology, Molecular; Positron-Emission Tomography - methods; Pyridines; Pyrrolidinones; Supranuclear Palsy, Progressive - metabolism; tau Proteins - metabolism; Tauopathies - metabolism
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awab282

The relationship between in vivo synaptic density and molecular pathology in primary tauopathies is key to understanding the impact of tauopathy on functional decline and in informing new early therapeutic strategies. In this cross-sectional observational study, we determine the in vivo relationship between synaptic density and molecular pathology in the primary tauopathies of progressive supranuclear palsy and corticobasal degeneration as a function of disease severity. Twenty-three patients with progressive supranuclear palsy and 12 patients with corticobasal syndrome were recruited from a tertiary referral centre. Nineteen education-, sex- and gender-matched control participants were recruited from the National Institute for Health Research 'Join Dementia Research' platform. Cerebral synaptic density and molecular pathology, in all participants, were estimated using PET imaging with the radioligands 11C-UCB-J and 18F-AV-1451, respectively. Patients with corticobasal syndrome also underwent amyloid PET imaging with 11C-PiB to exclude those with likely Alzheimer's pathology-we refer to the amyloid-negative cohort as having corticobasal degeneration, although we acknowledge other underlying pathologies exist. Disease severity was assessed with the progressive supranuclear palsy rating scale; regional non-displaceable binding potentials of 11C-UCB-J and 18F-AV-1451 were estimated in regions of interest from the Hammersmith Atlas, excluding those with known off-target binding for 18F-AV-1451. As an exploratory analysis, we also investigated the relationship between molecular pathology in cortical brain regions and synaptic density in subcortical areas. Across brain regions, there was a positive correlation between 11C-UCB-J and 18F-AV-1451 non-displaceable binding potentials (β = 0.4, t = 3.6, P = 0.001), independent of age or time between PET scans. However, this correlation became less positive as a function of disease severity in patients (β = -0.02, t = -2.9, P = 0.007, R = -0.41). Between regions, cortical 18F-AV-1451 binding was negatively correlated with synaptic density in subcortical areas (caudate nucleus, putamen). Brain regions with higher synaptic density are associated with a higher 18F-AV-1451 binding in progressive supranuclear palsy/corticobasal degeneration, but this association diminishes with disease severity. Moreover, higher cortical 18F-AV-1451 binding correlates with lower subcortical synaptic density. Longitudinal imaging is required